Tangji Gastric Bypass Stent Study for Obesity

Inclusion Criteria: 1. Aged 18-60 years, both male and female; 2. Obese patients with BMI ≥ 30 kg/m2, who are willing to be treated with Gastric Bypass Stent System or dietary intervention; 3. Patients with ASA I\~II grade; 4. The patient understands the onjective of the trial and is volunteered to participate in the trial and has signed the Informed Consent Form (ICF). Exclusion Criteria: 1. Have a weight loss of more than 4.5 kg in the past three months, or take weight-loss drugs in the past month; 2. Patients who used non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids in the past month; 3. Patients diagnosed with type 1 diabetes; 4. Patients with the function of islet β cell basically lost, C-peptide ≤ 1/2 of the normal low limit or low and flat C-peptide release curve under glucose load; 5. Patients with iron deficiency or iron deficiency anemia; 6. Patients with coagulation dysfunction who used aspirin and other anticoagulants in the past month; 7. Patients with severe liver and kidney dysfunction, and the serum creatinine concentration of greater than 180 μmol/L; 8. Patients with Class III heart function of NYHA or higher, or pulmonary dysfunction; 9. Patients who have undergone ERCP procedure, or have a history of cholecystitis or liver abscess; 10. Patients with duodenal ulcer, gastric ulcer or previous and existing pancreatitis; 11. Patients with gallstones (diameter ≥ 20 mm) with clinical symptoms; 12. Patients with thyroid dysfunction; 13. Patients with hemorrhage or potential hemorrhage in the digestive tract; 14. Patients with gastrointestinal tract anomalies, such as gastrointestinal tract atresia, or other conditions that would result in failed placement in the gastrointestinal tract; 15. Patients with a history of bowel obstruction or related diseases in the past year; 16. Patients with a history of systemic lupus erythematosus or scleroderma; 17. Patients with severe infections that are not controlled, not suitable for a procedure; 18. Patients with poor general condition and having endoscopic contraindications (as evaluated by the investigator); 19. Pregnant women or women having the plan for pregnancy; 20. Drug abusers or alcohol addicts or patients with uncontrollable mental illness; 21. Patients who participated in other clinical trials of drugs or medical devices before enrollment and do not reach the endpoint time limit; 22. Patients who participated in other clinical trials of drugs or medical devices before enrollment 3 months. 23. Patients with any other conditions evaluated by the investigators as unsuitable for participating in the trial.